Compare WLTH & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WLTH | EYPT |
|---|---|---|
| Founded | 2008 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | N/A | 2005 |
| Metric | WLTH | EYPT |
|---|---|---|
| Price | $10.57 | $14.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $12.86 | ★ $31.80 |
| AVG Volume (30 Days) | ★ 1.6M | 849.8K |
| Earning Date | 05-18-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,539,000.00 |
| Revenue This Year | $10.61 | N/A |
| Revenue Next Year | $23.50 | $863.07 |
| P/E Ratio | $10.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.20 | $5.37 |
| 52 Week High | $14.12 | $19.11 |
| Indicator | WLTH | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 70.80 | 54.32 |
| Support Level | $7.25 | $12.59 |
| Resistance Level | $14.12 | $14.54 |
| Average True Range (ATR) | 0.47 | 0.69 |
| MACD | 0.18 | 0.26 |
| Stochastic Oscillator | 92.28 | 85.57 |
Wealthfront Corp is a technology company that built a financial solutions platform for digital natives. Its platform is designed to address the needs of the wealth builders within these generations.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.